Cardiol Therapeutics Inc. (TSE:CRDL - Get Free Report)'s stock price traded up 1.8% on Thursday . The stock traded as high as C$2.23 and last traded at C$2.22. 181,842 shares changed hands during mid-day trading, an increase of 31% from the average session volume of 138,904 shares. The stock had previously closed at C$2.18.
Cardiol Therapeutics Stock Up 1.8 %
The company has a quick ratio of 6.84, a current ratio of 2.39 and a debt-to-equity ratio of 1.07. The stock has a market capitalization of C$157.93 million, a PE ratio of -5.05 and a beta of 0.70. The firm's fifty day moving average is C$2.69 and its 200-day moving average is C$2.85.
About Cardiol Therapeutics
(
Get Free Report)
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
See Also
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
